Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
Linrong Chen, Liuquan Han, Shujun Mao, et al.
European Journal of Medicinal Chemistry (2021) Vol. 216, pp. 113307-113307
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 168
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 51
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 46
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao‐Hong Chen, Erick Munoz, Dennis Ashong
Cancers (2024) Vol. 16, Iss. 3, pp. 663-663
Open Access | Times Cited: 16
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 96
Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues
Shi Shi, Yu Du, Yi Zou, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 6, pp. 5057-5071
Closed Access | Times Cited: 65
A bibliometric analysis of PROTAC from 2001 to 2021
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 65
Fluorinated Cycloalkyl Building Blocks for Drug Discovery
Oleksandr O. Grygorenko, Kostiantyn P. Melnykov, Serhii Holovach, et al.
ChemMedChem (2022) Vol. 17, Iss. 21
Closed Access | Times Cited: 57
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4014-4014
Open Access | Times Cited: 38
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 32
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
USP7 as an emerging therapeutic target: A key regulator of protein homeostasis
Ning-Jie Guo, Bo Wang, Yu Zhang, et al.
International Journal of Biological Macromolecules (2024) Vol. 263, pp. 130309-130309
Closed Access | Times Cited: 13
Application and challenges of nitrogen heterocycles in PROTAC linker
Yang Li, Junfeng Qu, Lizhi Jiang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116520-116520
Closed Access | Times Cited: 13
A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy
Bohan Ma, Donghua Liu, Zhe Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 12, pp. 10336-10349
Closed Access | Times Cited: 9
Targeting androgen receptor degradation with PROTACs from bench to bedside
Xiaojuan Jia, Xin Han
Biomedicine & Pharmacotherapy (2022) Vol. 158, pp. 114112-114112
Open Access | Times Cited: 34
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Jian Huang, Biyun Lin, Benyi Li
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 31
Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Jiayue Xi, Ruyue Zhang, Ke Chen, et al.
Bioorganic Chemistry (2022) Vol. 125, pp. 105848-105848
Closed Access | Times Cited: 30
E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities
Qiang Zou, Meng Liu, Kewei Liu, et al.
Cellular Oncology (2023) Vol. 46, Iss. 3, pp. 545-570
Open Access | Times Cited: 17
PROTACs in the Management of Prostate Cancer
Yedla Poornachandra, Ahmad O. Babalghith, Vindhya Vasini Andra, et al.
Molecules (2023) Vol. 28, Iss. 9, pp. 3698-3698
Open Access | Times Cited: 17
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Chao Wang, Yujing Zhang, Jie Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113906-113906
Closed Access | Times Cited: 40
A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives
Si Ha, Guoshun Luo, Hua Xiang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16128-16154
Closed Access | Times Cited: 24
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Hongyi Zhao, Minhang Xin, San‐Qi Zhang
Drug Development Research (2023) Vol. 84, Iss. 2, pp. 337-394
Closed Access | Times Cited: 16
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment
Baohua Xie, Bin Xu, Lilan Xin, et al.
Bioorganic Chemistry (2023) Vol. 137, pp. 106590-106590
Closed Access | Times Cited: 11
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Narayanaperumal Pravin, Krzysztof Jóźwiak
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116837-116837
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top